Norwegian version of this page

K.G. Jebsen Centre for B cell malignancies extended to 2024

The Centre has received a new allocation of NOK 9 million from Stiftelsen Kristian Gerhard Jebsen. The extension makes it possible to continue with important research in immunotherapy and precision medicine. The Centre is led by Professor Ludvig A. Munthe.

Image of Professor Ludvig A. Munthe and Associate Professor June Helen Myklebust.

The K.G. Jebsen Centre for B cell malignancies is headed by Professor Ludvig A. Munthe (left). Associate Professor June Helen Mykrebust (right) is the Centre's deputy head. Image: Terje Heiestad, Rolf Ottesen AS. 

The K.G. Jebsen Centre for B cell malignancies was established in 2018. The research at the Centre focuses on knowledge about B-cell cancer, i.e., blood cancer, lymphoma and multiple myeloma. The two-year extension entails that the Centre will receive funding for six years, from 2018 to 2024.

– We are happy and proud for the continued support from Stiftelsen Kristian Gerhard Jebsen to our research centre. This is a recognition of the work for a disease group for which there is still no curative treatment, comments Professor Ludvig A. Munthe, who is head of the Centre.

The faculty is grateful for both the award and the effort

Image of Pro-Dean for research, Jens Petter Berg
Pro-Dean for research, Jens Petter Berg. Image: Øystein Horgmo, UiO.

The Pro-Dean for research, Jens Petter Berg, on behalf of the Faculty of Medicine at the University of Oslo, is grateful for the award and for the efforts the researchers are making to develop new and advanced methods for treating cancer.

– I would like to congratulate Professor Ludvig A. Munthe and his staff at the K.G. Jebsen Centre for B cell malignancies for top marks from international experts and the renewed allocation of funds from Stiftelsen Kristian Gerhard Jebsen, Jens Petter Berg says.

 

Fantastic development and no big surprise

Image og Head of Department, Dag Kvale
Head of Department, Dag Kvale. Image: Øystein Horgmo, UiO.

In a comment, Dag Kvale, Head of Department at the Institute of Clinical Medicine, says:

– In recent years, the Institute has seen a fantastic development in and around this Centre, both academically and in the number of sub-projects. It was therefore no great surprise that the Centre received a very good expert evaluation, and correspondingly it was very satisfactory and deserved that the Centre receives extended support. The Institute congratulates the Centre management and the researchers and look forward to its continuation.


The extension makes it possible to test research findings in the clinic

One of the Centre’s strengths is that it has brought together laboratory researchers and clinicians from various medical disciplines. The Centre has made large, interdisciplinary research projects possible within its two pillars of immunotherapy and personalised treatment, so-called precision medicine. The goal is to be able to offer patients with various forms of B-cell cancer better treatment.

The Centre conducts more than 80 clinical trials, and over 30 of these are currently recruiting patients.

– The extension is very important. It allows us to continue with important projects that we have started in the first period. In addition, there are now several research findings from the laboratory that we can test in the clinic, in the form of new clinical studies, Associate Professor and the Centre's deputy head, June Helen Myklebust says.

Myklebust and her research group are studying lymphoma. They are working to gain a better understanding of why tumours in people who have received the same diagnosis, are different. In the long run, they want to give clinicians a tool that makes it possible to find out which treatment is best suited for each individual lymphoma patient.

– A better understanding of the cellular composition of the tumour microenvironment, including what types of immune cells are present, will have an impact on how a patient will respond to treatment, she explains.

Myklebust says that the close collaboration with clinicians has had a great impact on her research in the laboratory:

– The collaboration means that we are always aware of important clinical challenges that we can help answer with our laboratory research.

Head of the Centre, Professor Munthe, also emphasises the importance of the close collaboration with the clinic:

– This means that we can offer the latest therapies to patients who have few other treatment options, he says, and adds:

– The Centre links clinical research to ground-breaking fundamental research and to translational research. The same can be said about research-driven innovations tailored to provide new treatment options.

Talent from abroad is part of the Centre's success

The Centre has made it possible to recruit talented researchers from all over the world. This has been important for the Centre's success.

– With highly skilled and innovative people on the team, we can conduct much better research, June Helen Myklebust concludes.

Image of three researchers from the Myklebust group.
From left to right: Kanutte Huse, Jillian F. Wise and Chloé B. Steen. The three researchers are part of the Myklebust research group. Image: Terje Heiestad, Rolf Ottesen AS.

Contact

 

Note: 22.12.2021: "Kristian Gerhard Jebsen Foundation" was changed to "Stiftelsen Kristian Gerhard Jebsen" in the text, as this is the name that should be used also in English. Kristian Gerhard Jebsen Foundation is a separete foundation. 

Tags: K.G. Jebsen Centre, B-cell cancer, blood cancer, lymphoma, multiple myeloma, Ludvig A. Munthe, June Helen Myklebust, Stiftelsen Kristian Gerhard Jebsen By Elin Martine Doeland
Published Dec. 16, 2021 2:55 PM - Last modified Dec. 22, 2021 11:40 AM